Table 3.
Results of Various Studies25,26,28 Conducted to Evaluate the Effect of Ribavirin in Curing Cases of SSPE.
| Study name | Author (s) | Location | Study type | Result (s) |
|---|---|---|---|---|
| Subacute sclerosing panencephalitis: clinical phenotype, epidemiology, and preventive interventions 25 | Mohammed Mekki, Brian Eley, Diana Hardie, Jo M Wilmshurst | South Africa | Review | Ribavirin is associated with partial clinical improvement. Clinical benefit is brought through the maintenance of CSF levels with a subcutaneous continuous infusion mode of delivery. |
| Pharmacokinetics and effects of ribavirin following intraventricular administration for treatment of subacute sclerosing panencephalitis 28 | Mitsuaki Hosoya, Shuichi Mori, Akemi Tomoda, Kenji Mori, Yukio Sawaishi, Hiroshi Kimura, Shiro Shigeta, Hitoshi Suzuki | Japan | Clinical Trial | Intraventricular administration of ribavirin is effective against SSPE when CSF ribavirin concentration is maintained at a high level |
| Measles 26 | Paul A. Rota, William J Moss, Makoto Takeda, Rik L de Swart, Kimberly M Thompson, James L Goodson | USA | Review | Aerosolized or intravenous ribavirin provides some benefit in severe disease |